David Liu
Fortune : 199 193 $ au 30/06/2026
Fortune : 199 193 $ au 30/06/2026
David Liu is an Independent Director at Edesa Biotech, Inc. since 2025.
Dr. Liu is a Senior Analyst at Velan Capital Investment Management LP since 2023.
Former roles include Equity Research Associate at RBC Capital Markets LLC, Analyst at Iguana Healthcare Management LLC, and Analyst at Altium Capital Management LLC from 2019 to 2022.
Education includes an undergraduate degree from Stanford University conferred in 2007 and a doctorate from Cornell University.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
EDESA BIOTECH, INC. 0,28 % | 27/05/2026 | 24 501 ( 0,28 % ) | 199 193 $ | 30/06/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| EDESA BIOTECH, INC. | Directeur/Membre du Conseil | 12/02/2025 |
Velan Capital Investment Management LP
Velan Capital Investment Management LP Investment ManagersFinance Velan Capital manages a long/short investment strategy for their clients. | Analyst-Equity | 01/01/2023 |
| Sociétés | Poste | Fin |
|---|---|---|
Altium Capital Management LP
Altium Capital Management LP Investment ManagersFinance Altium Capital Managment focuses primarily on fundamental equity long/short strategies. Their investment universe is mostly concentrated in US-based small/micro-cap public companies, with significant near/medium-term catalysts, and those raising capital from institutional investors for the first time. The firm’s hedge fund invests in companies that provide progressive therapies. | Analyst-Equity | 01/12/2022 |
RBC Capital Markets LLC
RBC Capital Markets LLC Investment Banks/BrokersFinance Provides brokerage services | Analyst-Equity | - |
Iguana Healthcare Management LLC
Iguana Healthcare Management LLC Investment ManagersFinance Iguana Healthcare Management Healthcare’s investment objective is for its clients to maximum returns from investing long and short globally in public companies in the life sciences industry while actively managing both sector and global risk with an eye on capital preservation. The broad base of investment opportunities includes, but is not limited to companies focusing on biotechnology, branded pharmaceuticals, generic pharmaceutics, medical devices and medical supplies, healthcare service providers, and healthcare information technology. Iguana Healthcare clients’ portfolios are constructed using a multi-factorial approach with a focus on balancing risk and liquidity with expected returns on individual stocks and with their impact on upon overall portfolio concentration. Portfolios are constructed stock-by-stock and not sub-sector by sub-sector. | Analyst-Equity | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 7 |
|---|---|
Stanford University
Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cornell University
Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
RBC Capital Markets LLC
RBC Capital Markets LLC Investment Banks/BrokersFinance Provides brokerage services | Finance |
Iguana Healthcare Management LLC
Iguana Healthcare Management LLC Investment ManagersFinance Iguana Healthcare Management Healthcare’s investment objective is for its clients to maximum returns from investing long and short globally in public companies in the life sciences industry while actively managing both sector and global risk with an eye on capital preservation. The broad base of investment opportunities includes, but is not limited to companies focusing on biotechnology, branded pharmaceuticals, generic pharmaceutics, medical devices and medical supplies, healthcare service providers, and healthcare information technology. Iguana Healthcare clients’ portfolios are constructed using a multi-factorial approach with a focus on balancing risk and liquidity with expected returns on individual stocks and with their impact on upon overall portfolio concentration. Portfolios are constructed stock-by-stock and not sub-sector by sub-sector. | Finance |
Altium Capital Management LP
Altium Capital Management LP Investment ManagersFinance Altium Capital Managment focuses primarily on fundamental equity long/short strategies. Their investment universe is mostly concentrated in US-based small/micro-cap public companies, with significant near/medium-term catalysts, and those raising capital from institutional investors for the first time. The firm’s hedge fund invests in companies that provide progressive therapies. | Finance |
Edesa Biotech, Inc.
Edesa Biotech, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for treatment of chronic allergic contact dermatitis | Health Technology |
Velan Capital Investment Management LP
Velan Capital Investment Management LP Investment ManagersFinance Velan Capital manages a long/short investment strategy for their clients. | Finance |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national